Tahir Latif MD MBA
Professor, Internal Medicine, University of Cincinnati College of Medicine
Join to View Full Profile
234 Goodman StreetHematology/OncologyCincinnati, OH 45219
Phone+1 513-475-8500
Fax+1 513-584-4281
Dr. Latif is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Tech University, Rawls College of BusinessMBA, Health Care Management, 2007 - 2009
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2001 - 2004- Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Allama Iqbal Medical CollegeClass of 1996
Certifications & Licensure
OH State Medical License 2001 - 2026
NM State Medical License 2004 - 2012
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma Start of enrollment: 2018 Oct 29
Publications & Presentations
PubMed
- 3 citationsSystemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.Shuchi Gulati, Chih-Yuan Hsu, Surbhi Shah, Pankil K Shah, Rebecca Zon
JAMA Oncology. 2023-10-01 - 14 citationsImmune checkpoint inhibitors in liver transplant: a case series.Mark Rudolph, Shimul A Shah, Ralph Quillin, Kristina Lemon, Olugbenga Olowokure
Journal of Gastrointestinal Oncology. 2023-04-29 - 4 citationsRational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Schwieterman
Blood Advances. 2023-04-25
Press Mentions
Gender Disparities and Other DLBCL DevelopmentsJuly 28th, 2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
